Cargando…

Latency reversal agents modulate HIV antigen processing and presentation to CD8 T cells

Latency reversal agents (LRA) variably induce HIV re-expression in CD4 T cells but reservoirs are not cleared. Whether HIV epitope presentation is similar between latency reversal and initial infection of CD4 T cells is unknown yet crucial to define immune responses able to detect HIV-infected CD4 T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boucau, Julie, Das, Jishnu, Joshi, Neelambari, Le Gall, Sylvie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112239/ https://www.ncbi.nlm.nih.gov/pubmed/32196533 http://dx.doi.org/10.1371/journal.ppat.1008442

Ejemplares similares

A natural polymorphism of Mycobacterium tuberculosis in the esxH gene disrupts immunodomination by the TB10.4-specific CD8 T cell response
por: Sutiwisesak, Rujapak, et al.
Publicado: (2020)

Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure
por: Clutton, Genevieve Tyndale, et al.
Publicado: (2018)

HIV Controllers Exhibit Effective CD8(+) T Cell Recognition of HIV-1-Infected Non-activated CD4(+) T Cells
por: Monel, Blandine, et al.
Publicado: (2019)

Alteration of HIV epitope processing and presentation by HIV protease inhibitors
por: Kourjian, G, et al.
Publicado: (2012)

Latency reversal agents affect differently the latent reservoir present in distinct CD4(+) T subpopulations
por: Grau-Expósito, Judith, et al.
Publicado: (2019)

Inconsistent reversal of HIV-1 latency ex vivo by antigens of HIV-1, CMV, and other infectious agents
por: Vollbrecht, Thomas, et al.
Publicado: (2020)

NSC95397 is a Novel HIV Latency Reversing Agent
por: Nichols Doyle, Randilea, et al.
Publicado: (2023)

Mechanisms of HIV Protein Degradation into Epitopes: Implications for Vaccine Design
por: Rucevic, Marijana, et al.
Publicado: (2014)

Antigen Production After Latency Reversal and Expression of Inhibitory Receptors in CD8+ T Cells Limit the Killing of HIV-1 Reactivated Cells
por: Ruiz, Alba, et al.
Publicado: (2019)

Reanalysis of Gene Expression Profiles of CD4+ T Cells Treated with HIV-1 Latency Reversal Agents
por: Campos Coelho, Antonio Victor, et al.
Publicado: (2020)

The role of antigen presenting cells in the induction of HIV-1 latency in resting CD4(+) T-cells
por: Kumar, Nitasha A., et al.
Publicado: (2015)

Effect of HIV infection on the expression and the activity of the proteasome in primary CD4 T cells
por: Boucau, J, et al.
Publicado: (2012)

Control of Gammaherpesvirus Latency by Latent Antigen-Specific Cd8(+) T Cells
por: Usherwood, Edward J., et al.
Publicado: (2000)

A Conserved HIV-1-Derived Peptide Presented by HLA-E Renders Infected T-cells Highly Susceptible to Attack by NKG2A/CD94-Bearing Natural Killer Cells
por: Davis, Zachary B., et al.
Publicado: (2016)

HIV-1 Latency and Latency Reversal: Does Subtype Matter?
por: Sarabia, Indra, et al.
Publicado: (2019)

Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents
por: Marsden, Matthew D., et al.
Publicado: (2018)

HIV latency reversing agents act through Tat post translational modifications
por: Khoury, Georges, et al.
Publicado: (2018)

A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4(+) T-Cells to Recognition by Cytotoxic T-Lymphocytes
por: Jones, R. Brad, et al.
Publicado: (2016)

The Effect of Latency Reversal Agents on Primary CD8 + T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication
por: Walker-Sperling, Victoria E., et al.
Publicado: (2016)

Sensing of HIV-1 by TLR8 activates human T cells and reverses latency
por: Meås, Hany Zekaria, et al.
Publicado: (2020)

HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function
por: Garrido, Carolina, et al.
Publicado: (2016)

Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents
por: Gupta, Vipul, et al.
Publicado: (2018)

Structure-Activity Relationship Analysis of Benzotriazine Analogues as HIV-1 Latency-Reversing Agents
por: Sorensen, Eric S., et al.
Publicado: (2020)

Harmine enhances the activity of the HIV-1 latency-reversing agents ingenol A and SAHA
por: Taylor, Jared P., et al.
Publicado: (2020)

Discovering the Mechanisms of Oleodaphnone as a Potential HIV Latency-Reversing Agent by Transcriptome Profiling
por: Li, Shifei, et al.
Publicado: (2023)

Epigenetic Regulation of HIV-1 Sense and Antisense Transcription in Response to Latency-Reversing Agents
por: Li, Rui, et al.
Publicado: (2023)

Latency Reversing Agents: Kick and Kill of HTLV-1?
por: Schnell, Annika P., et al.
Publicado: (2021)

Impact of latency‐reversing agents on human macrophage physiology
por: Hany, Laurent, et al.
Publicado: (2022)

New Concepts in Therapeutic Manipulation of HIV-1 Transcription and Latency: Latency Reversal versus Latency Prevention
por: Lewis, Catherine A., et al.
Publicado: (2023)

A simple methodology to assess endolysosomal protease activity involved in antigen processing in human primary cells
por: Vaithilingam, Archana, et al.
Publicado: (2013)

The role of latency reversal in HIV cure strategies
por: Tanaka, Kiho, et al.
Publicado: (2022)

The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function
por: Clutton, G., et al.
Publicado: (2016)

Thalidomide as a Potential HIV Latency Reversal Agent: Is It the Right Time to Forget the Ancestral Sins?
por: Vignesh, Ramachandran, et al.
Publicado: (2017)

Polyanionic carbosilane dendrimers as a new adjuvant in combination with latency reversal agents for HIV treatment
por: Relaño-Rodríguez, Ignacio, et al.
Publicado: (2019)

Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs
por: Ait-Ammar, Amina, et al.
Publicado: (2020)

New Latency Reversing Agents for HIV-1 Cure: Insights from Nonhuman Primate Models
por: Bricker, Katherine M., et al.
Publicado: (2021)

Identification of celastrol as a novel HIV-1 latency reversal agent by an image-based screen
por: Liu, Hongbing, et al.
Publicado: (2021)

Are BET Inhibitors yet Promising Latency-Reversing Agents for HIV-1 Reactivation in AIDS Therapy?
por: Salahong, Thanarat, et al.
Publicado: (2021)

Anti-latency agents to purge HIV reservoirs
por: Moreno, Santiago
Publicado: (2012)

Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4(+) T Cells
por: Kulpa, Deanna A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7nr802nslnath10lp704t6nrdv